EP1141722A1 - Pyk2 (raftk) et inflammation - Google Patents

Pyk2 (raftk) et inflammation

Info

Publication number
EP1141722A1
EP1141722A1 EP98966125A EP98966125A EP1141722A1 EP 1141722 A1 EP1141722 A1 EP 1141722A1 EP 98966125 A EP98966125 A EP 98966125A EP 98966125 A EP98966125 A EP 98966125A EP 1141722 A1 EP1141722 A1 EP 1141722A1
Authority
EP
European Patent Office
Prior art keywords
pyk2
compounds
disease
interaction
binding partner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98966125A
Other languages
German (de)
English (en)
Inventor
Joseph Schlessinger
Mitsuhiko Okigaki
Mikhail Gishizky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Priority to EP05008803A priority Critical patent/EP1630559A3/fr
Publication of EP1141722A1 publication Critical patent/EP1141722A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de manière générale les domaines de l'immunologie et de la médecine et plus particulièrement le domaine de la transduction de signal cellulaire. L'invention concerne, entre autre, des diagnostics, des traitements et l'identification de traitement de maladies ou troubles particuliers associés à l'inflammation caractérisés par une interaction entre un polypeptide PYK2 et un agent de liaison naturel.
EP98966125A 1998-12-30 1998-12-31 Pyk2 (raftk) et inflammation Withdrawn EP1141722A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05008803A EP1630559A3 (fr) 1998-12-30 1998-12-31 PYK2 (RAFTK) et inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/027871 WO2000040971A1 (fr) 1998-12-31 1998-12-31 Pyk2 (raftk) et inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05008803A Division EP1630559A3 (fr) 1998-12-30 1998-12-31 PYK2 (RAFTK) et inflammation

Publications (1)

Publication Number Publication Date
EP1141722A1 true EP1141722A1 (fr) 2001-10-10

Family

ID=22268584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98966125A Withdrawn EP1141722A1 (fr) 1998-12-30 1998-12-31 Pyk2 (raftk) et inflammation

Country Status (3)

Country Link
EP (1) EP1141722A1 (fr)
AU (1) AU2209899A (fr)
WO (1) WO2000040971A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1228766A1 (fr) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
EP1401411A2 (fr) * 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
US20050059621A1 (en) * 2003-06-06 2005-03-17 Irene Griswold-Prenner Methods for using modulators of proline-rich tyrosine kinase 2
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2719708B1 (fr) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Matériau et procédés de traitement ou de prévention de maladies associées à des HER-3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262195T3 (es) * 1996-10-11 2006-11-16 Sugen, Inc. Proteinas rdgb.
ATE271603T1 (de) * 1996-12-11 2004-08-15 Sugen Inc Identifizierungsverfahren für substanzen die an das pyk2 polypeptid binden
CA2277544A1 (fr) * 1997-02-11 1998-08-13 Merck & Co., Inc. Identification d'inhibiteurs de la proteine tyrosine-kinase 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0040971A1 *

Also Published As

Publication number Publication date
AU2209899A (en) 2000-07-24
WO2000040971A1 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
US7902165B2 (en) Use of AIM3 acting as a tumor suppressor
WO1998045708A1 (fr) Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
US5260200A (en) Isolated DNA encoding an insulin receptor substrate
JP2002537407A (ja) 血清コレステロールを調節するための組成物及び方法。
US20080206232A1 (en) Compositions and Methods For Modulating Pgc-1Beta to Treat Lipid-Related Diseases and Disorders
EP1141722A1 (fr) Pyk2 (raftk) et inflammation
TW200538109A (en) Furosemide modulators of HM74
EP3094726B1 (fr) Matériels biologiques et leurs utilisations thérapeutiques
US20140186372A1 (en) Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
US7364870B2 (en) MK2 interacting proteins
EP1421218A2 (fr) Modele de maladie auto-immune et procedes permettant d'identifier des agents actifs contre une maladie auto-immune
US6861442B1 (en) PYK2 and inflammation
EP1630559A2 (fr) PYK2 (RAFTK) et inflammation
PT90019B (pt) Processo para a preparacao e purificacao de factor de choque termico humano
US7160681B2 (en) Method for regulating cell growth and assays related thereto
AU8395998A (en) Pak kinase genes and polypeptides and methods of use thereof
JPH06503647A (ja) ヒトホスホリパーゼ活性化タンパク質および慢性関節リウマチの診断の方法
JP2004527724A (ja) Ｐｙｋ２（ｒａｆｔｋ）及び炎症
EP1169054B1 (fr) Pronostic de maladies associees a ptp lar
Lv et al. The pentapeptide PLNPK inhibits systemic lupus erythematosus-associated renal damage
WO2002042489A1 (fr) Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t
WO1998005349A1 (fr) Nouveau procede de detection et de traitement du cancer
WO2011014816A1 (fr) Thérapie ciblée pour la protéine wd repeat 79
WO2001004629A9 (fr) Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective
JP2002519008A (ja) Ｔｅｆ−３活性を阻害するための方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051019